
FDA ApprovedUnited States
New Treatment for Immune-Related Anemia in Teens and Adults
Imaavy (nipocalimab-aahu) — neonatal Fc receptor blocker for warm autoimmune hemolytic anemia in adults and adolescents 12 years and older after corticosteroid exposure
FDA approval on 25 August 2026 for Imaavy (nipocalimab-aahu) injection — a neonatal Fc receptor (FcRn) blocker — for warm autoimmune hemolytic…
This is for people 12 years and older with warm autoimmune hemolytic anemia who are currently on or have…